hydroxychloroquine has been researched along with Retinal Degeneration in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Retinal Degeneration: A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304)
Excerpt | Relevance | Reference |
---|---|---|
"Cohort of 301 patients receiving long-term hydroxychloroquine therapy at Kaiser Permanente Northern California who underwent a minimum of 4 OCT studies that included Early Treatment Diabetic Retinopathy Study (ETDRS) retinal thickness values over a minimum of 4 years." | 4.12 | Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity. ( Marmor, MF; Melles, RB, 2022) |
"A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening." | 4.12 | Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022) |
"In untreated rheumatoid arthritis 20% of the patients has a EOG Lp/Dt ratio lower than the lower 5% limit calculated for normal patients." | 1.27 | The EOG in rheumatoid arthritis. ( Broekhuyse, RM; Pinckers, A, 1983) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 3 (42.86) | 2.80 |
Authors | Studies |
---|---|
Melles, RB | 1 |
Marmor, MF | 1 |
Joharjy, H | 1 |
Pisella, PJ | 1 |
Audo, I | 1 |
Le-Lez, ML | 1 |
Delavar, A | 3 |
Baxter, SL | 3 |
Yusuf, IH | 1 |
Lotery, AJ | 1 |
Ardern-Jones, MR | 1 |
Yao, J | 1 |
Qiu, Y | 1 |
Frontera, E | 1 |
Jia, L | 1 |
Khan, NW | 1 |
Klionsky, DJ | 1 |
Ferguson, TA | 1 |
Thompson, DA | 1 |
Zacks, DN | 1 |
Pinckers, A | 1 |
Broekhuyse, RM | 1 |
Reich, H | 1 |
1 review available for hydroxychloroquine and Retinal Degeneration
Article | Year |
---|---|
[Acrodermatitis enteropathica. Clinical picture, life-saving treatment, therapy-induced blindness].
Topics: Acrodermatitis; Blindness; Gastrointestinal Diseases; Humans; Hydroxychloroquine; Infant; Iodoquinol | 1973 |
6 other studies available for hydroxychloroquine and Retinal Degeneration
Article | Year |
---|---|
Rapid Macular Thinning Is an Early Indicator of Hydroxychloroquine Retinal Toxicity.
Topics: Antirheumatic Agents; Diabetic Retinopathy; Humans; Hydroxychloroquine; Retina; Retinal Degeneration | 2022 |
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxy | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018.
Topics: Humans; Hydroxychloroquine; Mass Screening; Patient Education as Topic; Practice Guidelines as Topic | 2018 |
Inhibiting autophagy reduces retinal degeneration caused by protein misfolding.
Topics: Animals; Autophagy; Autophagy-Related Protein 5; Beclin-1; Hydroxychloroquine; Mice, Inbred C57BL; M | 2018 |
The EOG in rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Electrooculography; Female; Humans; H | 1983 |